<DOC>
	<DOCNO>NCT00005624</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness CI-994 treating patient advance myeloma .</brief_summary>
	<brief_title>CI-994 Treating Patients With Advanced Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine antitumor activity CI-994 patient advance myeloma . II . Determine response rate , response duration , overall survival patient population treatment regimen . III . Determine safety treatment patient . OUTLINE : This multicenter study . Patients receive CI-994 orally daily . Treatment continue absence disease progression unacceptable toxicity . Patients follow 30 day every 2 month . PROJECTED ACCRUAL : A total 8-63 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIA IIIA myeloma measurable M component serum urine Progressing disease conventional chemotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 8 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 75,000/mm3 ( transfusion independent ) Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) AST/ALT great 2 time ULN Renal : Creatinine great 1.5 time ULN Calcium great 12 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No life threaten illness unrelated tumor No concurrent serious infection No prior malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix Must capable swallow intact medication capsule No medical psychiatric condition would prevent write informed consent PRIOR CONCURRENT THERAPY : Biologic therapy : At least 14 day since prior immunologic agent No concurrent immunologic agent Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : At least 2 week since prior high dose corticosteroid No concurrent anticancer hormonal therapy No concurrent corticosteroid Radiotherapy : At least 3 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>plasma cell neoplasm</keyword>
</DOC>